Related Experiment Video
Updated: Aug 12, 2026
07:45
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
Neuronopathic forms of Gaucher's disease
A Erikson1, B Bembi, R Schiffmann
1Department of Paediatrics, University of Umeå, Sweden.
Bailliere'S Clinical Haematology
|March 14, 1998
Summary
Neuronopathic Gaucher disease presents diverse symptoms, and while enzyme replacement therapy (ERT) treats systemic issues, it rarely reverses neurological deficits. New therapies like gene therapy are needed for brain complications.
Area of Science:
- Neurology
- Genetics
- Biochemistry
Background:
- Neuronopathic Gaucher disease (GD) exhibits varied clinical presentations and neurological deficits.
- Brain pathology in GD is known, but the mechanism of neuronal dysfunction from glucocerebrosidase deficiency remains unclear.
- Genetic mutations in glucocerebrosidase poorly correlate with individual patient phenotypes in Types 2 and 3 GD.
Purpose of the Study:
- To summarize the current understanding of neuronopathic Gaucher disease.
- To highlight the limitations of existing treatments for neurological symptoms.
- To introduce the need for novel therapeutic strategies targeting neuronal dysfunction.
Main Methods:
- Review of existing literature on Gaucher disease.
- Analysis of clinical manifestations and genetic mutations.
- Evaluation of the efficacy of enzyme replacement therapy (ERT).
Main Results:
- Enzyme replacement therapy (ERT) effectively addresses systemic manifestations of Gaucher disease.
- Neurological deficits in neuronopathic Gaucher disease are seldom reversed by ERT.
- Current genetic understanding does not accurately predict individual patient outcomes.
Conclusions:
- Neuronopathic Gaucher disease requires treatments that can effectively cross the blood-brain barrier.
- Development of gene therapy and direct neuronal enzyme delivery are crucial for managing neurological symptoms.
- Further research is needed to elucidate the mechanisms of neuronal dysfunction in Gaucher disease.
Related Concept Videos
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...